Zai Lab (ZLAB) Plunges 8.61% on Insider Selling, Earnings Miss

Zai Lab (ZLAB) shares fell 8.61% intraday, marking the lowest level since January 2025, with a cumulative decline of 26.25% over the past four days.

One of the key factors influencing Zai Lab's stock price is the recent insider selling by the company's CFO, Yajing Chen. Chen sold shares on two occasions in early April 2025, which may have impacted investor sentiment. The sales occurred on April 4th and April 2nd, with the latter being a larger transaction.

Additionally, Zai Lab's recent quarterly earnings report fell short of analyst expectations. The company reported an EPS of ($0.80), which was below the consensus estimate of ($0.61). This financial underperformance has likely contributed to the stock's decline, as investors reassess the company's prospects.

Analyst ratings and price targets for Zai Lab have been mixed. Bank of America maintained a "neutral" rating but increased their price objective to $36.10. JPMorgan Chase & Co. raised their price target to $51.00 with an "overweight" rating. These varied opinions reflect the uncertainty surrounding the company's future performance and may be influencing investor decisions.